FNP-223, previously known as ASN90, is a reversible and substrate-competitive O-GlcNAcase enzyme inhibitor. The oral investigational drug is expected to rapidly increase O-GlcNAcylated tau proteins, ...

In the early stages, progressive supranuclear palsy can be difficult to distinguish from Parkinson's disease. How can gait characteristics be used to identify distinguishing features of PSP?

Progressive supranuclear palsy (PSP) affects persons in their late 60s to 70s, because of the shrinkage of the upper ...

So, let’s talk about faith. I’m no rabbi or scholar, and I’m not trying to write a religious work. But putting my thoughts ...

Patients with PSP often had severe postural instability at onset, symmetric parkinsonism, vertical supranuclear gaze palsy, speech and frontal lobe-type features.

When progressive supranuclear palsy (PSP), a rare neurodegenerative disorder, started affecting his movement, his wife and ...

/ April 28, 2025 / The Progressive Supranuclear Palsy (PSP) Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco [UCSF]), Irene Litvan (University of California ...

“When she would fall in public, people just assumed she was drunk,” said Glenn. “One time she fell backwards on the steps and ...